| 03/12/2013 | ||||||||||
 08.00 - 09.00 | Registration and Refreshments | |||||||||
| 09.00 - 09.05 | Opening Remarks from the Chair Andrew Jack, Pharmaceutical Correspondent, Financial Times
| |||||||||
| 09.05 - 09.30 | FT View from the Top Opening Keynote Interview Pascal Soriot, Chief Executive Officer, AstraZeneca in conversation with Andrew Jack | |||||||||
| 09.30 - 10.30 | Panel: Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust Dr Marijn Dekkers, Chairman of the Board of Directors, Bayer
PANELISTS:
William Burns, Former Chief Executive, Roche Pharmaceuticals and Independent Director on several Boards
Darren Campili, Managing Director, Head of Healthcare Banking EMEA, Deutsche Bank
Nikos Dedes, Chair, Positive Voice, Greece & Member of the EMA Management Board
Rogier Snijdewind, Adviser, Responsible Investment, PGGM Investment
With recent surveys revealing pharmaceutical companies now ranking in trust perceptions below producers of spirits and tobacco, and physicians basing prescribing decisions as much on brands as on products, the need for pharmaceutical companies to understand and address the factors contributing to poor reputation has never been greater. Brands are the ‘currency’ of life science companies, driving business, enabling them to attract and retain talent, and ensuring they are perceived as partners of choice in today’s increasingly networked healthcare economy. How can pharma companies restore reputation and increase trust? With mistrust of high pricing of drugs and clinical trial results at an all time high, should governments, rather than pharma companies fund research? What role can transparency play? How can social media be harnessed to improve reputation amongst partners and patients? What is the patient’s view of value in pharma?
| |||||||||
| 10:30 - 11:00 | Networking Coffee Break | |||||||||
| 11.00 - 11.25 | Keynote Interview Professor David Haslam, CBE, Chair, National Institute for Health and Care Excellence (NICE) | |||||||||
| 11.25 - 12.15 | The New Pharma Workforce – The Skills to Lead? Said Darwazah, Chief Executive Officer, Hikma
PANELISTS:
Jacques Bouwens, Head, Global Healthcare, Russell Reynolds Associates
Dietmar Eidens, Executive Vice President, Human Resources, MerckSerono
Jeremy Levin, Former President and CEO, Teva Pharmaceutical
Industries
Professor Paul Workman, Deputy Chief Executive, The Institute of Cancer Research (ICR)
The changing landscape of the industry-the increasing focus
on globalisation, on outcomes, on external collaborations, and on building
patient centred services and business, for instance- will require a significant
shift in the skills base, and leadership qualities required by life science
companies if they are to meet the new challenges they face head on. Cross
disciplinary skills in research and economics, in data analytics, as well as
leadership qualities focussed on the ability to communicate value to the industry’s
multiple stakeholders will be at a premium. Are universities preparing people
with the right skills and talent for the tasks ahead? How effectively are life
science companies recognising the value of diversity and harnessing the talent
across their global organisations to develop potential new revenue streams and
better understand the aspirations, needs and preferences of their customers?
Does the industry have the leadership skills it needs to take the industry
forward?
| |||||||||
| 12.15 - 1.35 | Lunch | |||||||||
| 13.35 - 14.00 | Keynote Address | |||||||||
| 14.00 - 15.00 | Can the Industry Successfully Capitalise on the Potential of Personalised Medicine? Daniel O’Day, Chief Operating Officer, Pharmaceuticals, Roche
PANELISTS:
Edward Abrahams, President, Personalized Medicine Coalition
Stephen Eck, Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development
Luke Johnson, Chairman, Risk Capital Partners, Chairman, The Institute of Cancer Research (ICR)
Hakan Sakul, Executive Director, Head of Diagnostics Worldwide R&D, Pfizer
Some decade or so since the completion of the human genome
project there has been tremendous scientific progress in genomics. However
despite the high expectations, it is now considered less likely that genomics
will have a major clinical effect on the prognosis of common complex diseases,
and despite the identification of numerous gene-drug associations, few have
been incorporated into clinical practice. What are the challenges and barriers
and how can they be addressed to ensure that the potential of personalised
medicine becomes a reality in improving the health outcomes of patients, and a
commercial success for life science companies? Do the economics of personalised
medicine stack up?
| |||||||||
| 15.00 - 15.25 | Keynote Interview: Accelerating Innovation and Collaboration Across Clinical R&D and Healthcare Jonathan Sheldon, Global Vice President, Health Sciences, Oracle Health Sciences in conversation with Andrew Jack | |||||||||
| 15.25 - 15.55 | Networking Coffee Break | |||||||||
| 15.55 - 16.55 | The Power of Networks, Partnerships and Alliances - Strategies for Effective R&D Collaboration MODERATOR:
Andrew Jack, Pharmaceutical Correspondent, Financial Times
PANELISTS:
Dr Jean-Paul Kress, President and Chief Executive Officer, Sanofi Pasteur MSD
Dr Denis Lacombe, Director, European Organisation for Research and Treatment of Cancer (EORTC)
Ciaran Murray, Chief Executive Officer, ICON plc
Professor Sir John Tooke, Vice Provost (Health), Head of
Timothy Wright, Global Head, Development , Novartis Pharmaceuticals
| |||||||||
| 16.55 - 17.45 | The Transformative Role of Real World Data
Mike Standing, COO, Monitor Deloitte Europe Christopher Corsico, Corporate Senior Vice President, Medicine, Quality, Regulatory, Pharmacovigilance Ciarán Devane, Chief Executive, Macmillan Cancer Support Joan Dzenowagis, Senior Scientist-eHealth, World Health Organization Dr Lee Newcomer,Senior Vice President, UnitedHealthcare Dr John Parkinson, Director, Clinical Practice Research Datalink (CPRD) Vast amount of annoymised healthcare data records are now available either in public systems or in private networks enabling detailed tracking of how patients are treated in the real world. This creates significant opportunities for pharma for more focused R&D, patient targeting and pricing for outcomes. For hospital systems, this creates an opportunity to build new partnerships with pharma companies to ensure that medical interventions are targeted effectively and can be priced according to outcomes. It enables both pharma and providers to understand how their actions jointly influence patient outcomes, enabling new forms of collaboration. The question is – who is ready for this change in using data to fundamentally change how pharma and the healthcare system interacts? How fast will this change happen? What concerns exist? Does the healthcare system trust pharma and vice versa?
| |||||||||
| 17.45 - 17.50 | Closing Remarks from the Chair and Networking Cocktail Reception | |||||||||
| 18.50 | Close | |||||||||
| 04/12/2013 | |||||
| 08.15 - 09.00 | Registration and Refreshments | ||||
| 09.00 - 09.05 | Opening Remarks from the Chair | ||||
| 09.05 - 9.30 | Keynote Address | ||||
| 9:30 - 9:55 | CEO Interview Eyal Desheh, Acting President and CEO, Teva Pharmaceutical Industries in conversation with Andrew Jack
| ||||
| 9.55 - 10.55 | Panel: Europe in Crisis - Managing for Uncertainty Reynold W. (Pete) Mooney, Global Leader, Life Sciences and Health Care, Deloitte
PANELISTS:
Richard Bergström, Director General, European Association of Pharmaceutical Industries and Associations (EFPIA)
Roberto Gradnik, Chief Executive Officer, Stallergenes, President, European Biopharmaceutical Enterprises (EBE)
Yann Le Cam, Chief Executive Officer, European Organisation for Rare Diseases, EURORDIS
Miklós Szócska, Minister of State for Health, Ministry of Human Resources,
The ongoing economic crisis and related austerity measures
in | ||||
| 10.55 - 11.15 | Networking Coffee Break | ||||
| 11:15 - 12:15 | Unlocking Africa’s Potential PANELISTS:
Kofi Amegashie, Managing Executive, Africa, Adcock Ingram Healthcare
Jane Griffiths, Group Chairman, Janssen Europe, Middle East and Africa
John Howe III, President and CEO, Project Hope
Feng Zhao, Health Division Manager, African Development Bank
With strong macroeconomic fundamentals, a shifting disease profile, improved
healthcare spending and a rising middle class, Africa is increasingly seen as
the frontrunner for life science opportunities in emerging markets. Spending on
pharma products across the continent is set to rise from a current $18bn
to $30bn by 2016 and $45bn by 2020 in line with economic growth rates of 10.6% in
a large majority of African markets. What are the innovative approaches and
strategies life science and healthcare companies are adopting to overcome
hurdles (e.g. distribution, health literacy, product safety. pricing) and to
build successful and sustainable, businesses and increase patient access in
| ||||
| 12.15 - 12.20 | Closing Remarks from the Chair | ||||
| 12.20 | Lunch | ||||
